ArticleOncology letters2026
Efficacy of circulating tumour DNA in guiding postoperative adjuvant chemotherapy for resectable colorectal cancer: A meta-analysis based on cohort studies.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The value of circulating tumour DNA (ctDNA) in resectable colorectal cancer (CRC) remains unclear. The present study evaluated the efficacy of ctDNA-guided adjuvant chemotherapy (ACT) in patients with resectable CRC after surgery. A systematic search was conducted in PubMed, Web of Science, EMBASE and the Cochrane Library databases for relevant studies published from January 2010 to July 2026. The inclusion criteria were studies that: i) Included patients with resectable CRC who underwent postoperative ctDNA testing before ACT initiation; ii) stratified the assessment of ACT efficacy based on ctDNA test results; and iii) reported recurrence-free survival (RFS) and/or overall survival (OS). The hazard ratio (HR) and 95% confidence interval (CI) were used to evaluate the results. The meta-analysis included 4 cohort studies and 1 randomized controlled trial, involving 2,081 evaluable patients with resectable CRC (441 cases in the ctDNA-positive group and 1,640 cases in the ctDNA negative group). Among the patients positive for ctDNA, the RFS rate (HR, 0.34; 95% CI, 0.16-0.73; P=0.006) and OS rate (HR, 0.40; 95% CI, 0.20-0.81; P=0.01) of the group that received ACT were significantly improved compared with those in patients who did not receive ACT. Among the patients negative for ctDNA, there was no statistically significant difference in the RFS rate (HR, 1.05; 95% CI, 0.70-1.60; P=0.802) and OS rate (HR, 0.66; 95% CI, 0.28-1.56; P=0.348) between the ACT and non-ACT groups. Therefore, the present study revealed that ctDNA testing may serve as a marker for guiding ACT in patients with resectable CRC after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.